Effects of triptolide on bone marrow‑derived mesenchymal stem cells from patients with multiple myeloma

Wu,Haiying; Wu,Yuanting; Ren,Li; Zhai,Wo; Jiang,Yuxia; Guo,Shuping; Tao,Diehong; Su,Chuanyong; Chen,Zhilu; Jiang,Huifang

doi:10.3892/etm.2019.7373

Effects of triptolide on bone marrow‑derived mesenchymal stem cells from patients with multiple myeloma

Authors:
- Haiying Wu
- Yuanting Wu
- Li Ren
- Wo Zhai
- Yuxia Jiang
- Shuping Guo
- Diehong Tao
- Chuanyong Su
- Zhilu Chen
- Huifang Jiang
View Affiliations

Affiliations: Department of Hematology, Tongde Hospital of Zhejiang Province, Hangzhou, Zhejiang 310012, P.R. China, The Second Clinical Medical College, Zhejiang Chinese Medical University, Hangzhou, Zhejiang 310053, P.R. China
Published online on: March 12, 2019 https://doi.org/10.3892/etm.2019.7373
Pages: 3291-3298
Copyright: © Wu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Triptolide (TPL), an extract of the Chinese herb Tripterygium wilfordii Hook F, is a potent anti‑inflammatory agent that further possesses anticancer activity. Its antiproliferative effects are well established. Only few studies have focused on TPL as a potential treatment in multiple myeloma (MM). In the current study, bone marrow‑derived mesenchymal stem cells (BMMSCs) from patients with MM were isolated and treated with TPL at varying concentrations. Thalidomide is currently used as a positive control drug in the treatment of MM. Cell Counting kit‑8 assays were performed to assess proliferation activity and flow cytometry with Annexin V‑fluorescein/propidium iodide was used to detect cell apoptosis of TPL‑treated BMMSCs. Reverse transcription‑quantitative polymerase chain reaction assays were applied to measure interleukin (IL)‑6, IL‑1β and stem cell factor (SCF or Kit ligand) mRNA expression and western blot assays were performed to analyze transcription factor p65 (P65) expression in TPL‑treated BMMSCs. ELISA was applied to measure vascular endothelial growth factor (VEGF) levels in the supernatant of the cultured and treated BMMSCs. TPL treatment significantly inhibited BMMSC proliferation compared with the untreated control (P<0.05). At 48 h following TPL treatment, a Cell Counting kit‑8 study was performed and the IC50 value was determined at 101.55±2.45 ng/ml. Apoptotic rates were observed to increase with increasing concentrations of TPL (P<0.001), and IL‑6, IL‑1β and SCF mRNA expression was significantly decreased with increasing TPL (P<0.001). P65 expression following TPL treatment was significantly decreased compared with the untreated control (P<0.05). VEGF levels were significantly reduced in the presence of increasing amounts of TPL (P<0.05). These findings suggest that TPL inhibited BMMSC growth and improved the bone marrow hematopoietic microenvironment by decreasing IL‑6, IL‑1β and SCF mRNA expression, subsequently inhibiting the proliferation of MM cells. Therefore, TPL may be used in the future to treat patients with MM.

View Figures

View References

1	Engelhardt M, Terpos E, Kleber M, Gay F, Wäsch R, Morgan G, Cavo M, van de Donk N, Beilhack A, Bruno B, et al: European Myeloma Network recommendations on the evaluation and treatment of newly diagnosed patients with multiple myeloma. Haematologica. 99:232–242. 2014. View Article : Google Scholar : PubMed/NCBI
2	Gu WZ and Brandwein SR: Inhibition of type II collagen-induced arthritis in rats by triptolide. Int J Immunopharmacol. 20:389–400. 1998. View Article : Google Scholar : PubMed/NCBI
3	Cibere J, Deng Z, Lin Y, Ou R, He Y, Wang Z, Thorne A, Lehman AJ, Tsang IK and Esdaile JM: A randomized double blind, placebo controlled trial of topical Tripterygium wilfordii in rheumatoid arthritis: Reanalysis using logistic regression analysis. J Rheumatol. 30:465–467. 2003.PubMed/NCBI
4	Liu H, Liu ZH, Chen ZH, Yang JW and Li LS: Triptolide: A potent inhibitor of NF-kappa B in T-lymphocytes. Acta Pharmacol Sin. 21:782–786. 2000.PubMed/NCBI
5	Zhao G, Vaszar LT, Qiu D, Shi L and Kao PN: Anti-inflammatory effects of triptolide in human bronchial epithelial cells. Am J Physiol Lung Cell Mol Physiol. 279:L958–L966. 2000. View Article : Google Scholar : PubMed/NCBI
6	Qiu D, Zhao G, Aoki Y, Shi L, Uyei A, Nazarian S, Ng JC and Kao PN: Immunosuppressant PG490 (triptolide) inhibits T-cell interleukin-2 expression at the level of purine-box/nuclear factor of activated T-cells and NF-kappaB transcriptional activation. J Biol Chem. 274:13443–13450. 1999. View Article : Google Scholar : PubMed/NCBI
7	Zhou HF, Niu DB, Xue B, Li FQ, Liu XY, He QH, Wang XH and Wang XM: Triptolide inhibits TNF-alpha, IL-1 beta and NO production in primary microglial cultures. Neuroreport. 14:1091–1095. 2003. View Article : Google Scholar : PubMed/NCBI
8	Hu KB, Liu ZH, Liu D and Li LS: Inhibition of vascular endothelial growth factor expression and production by triptolide. Planta Med. 68:368–369. 2002. View Article : Google Scholar : PubMed/NCBI
9	Kim JH and Park B: Triptolide blocks the STAT3 signaling pathway through induction of protein tyrosine phosphatase SHP-1 in multiple myeloma cells. Int J Mol Med. 40:1566–1572. 2017. View Article : Google Scholar : PubMed/NCBI
10	Johnson SM, Wang X and Evers BM: Triptolide inhibits proliferation and migration of colon cancer cells by inhibition of cell cycle regulators and cytokine receptors. J Surg Res. 168:197–205. 2011. View Article : Google Scholar : PubMed/NCBI
11	Ding J, Huang S, Wang Y, Tian Q, Zha R, Shi H, Wang Q, Ge C, Chen T, Zhao Y, et al: Genome-wide screening reveals that miR-195 targets the TNF-/NF-κB pathway by down-regulating IκB kinase alpha and TAB3 in hepatocellular carcinoma. Hepatology. 58:654–666. 2013. View Article : Google Scholar : PubMed/NCBI
12	Korde N, Kristinsson SY and Landgren O: Monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM): Novel biological insights and development of early treatment strategies. Blood. 117:5573–5581. 2011. View Article : Google Scholar : PubMed/NCBI
13	Buenrostro D, Mulcrone PL, Owens P and Sterling JA: The bone microenvironment: A fertile soil for tumor growth. Curr Osteoporos Rep. 14:151–158. 2016. View Article : Google Scholar : PubMed/NCBI
14	Zipori D: The hemopoietic stem cell niche versus the microenvironment of the multiple myeloma-tumor initiating cell. Cancer Microenviron. 3:15–28. 2010. View Article : Google Scholar : PubMed/NCBI
15	Ghobrial IM: Myeloma as a model for the process of metastasis: Implications for therapy. Blood. 120:20–30. 2012. View Article : Google Scholar : PubMed/NCBI
16	Wallace SR, Oken MM, Lunetta KL, Panoskaltsis-Mortari A and Masellis AM: Abnormalities of bone marrow mesenchymal cells in multiple myeloma patients. Cancer. 91:1219–1230. 2001. View Article : Google Scholar : PubMed/NCBI
17	Abe M: Development of the therapies targeting the interaction of myeloma cells with its bone marrow microenvironment. Rinsho Ketsueki. 54:522–532. 2013.(In Japanese). PubMed/NCBI
18	Mizuno H, Kikuta J and Ishii M: Bone and stem cells. Intravital imaging of bone marrow microenvironment. Clin Calcium. 24:541–546. 2014.(In Japanese). PubMed/NCBI
19	Verger E, Salamero M and Conill C: Can Karnofsky performance status be transformed to the Eastern Cooperative Oncology Group score scoring scale and vice versa? Eur J Cancer 28A. 1328–1330. 1992. View Article : Google Scholar
20	Rajkumar SV, Dimopoulos MA, Palumbo A, Blade J, Merlini G, Mateos MV, Kumar S, Hillengass J, Kastritis E, Richardson P, et al: International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 15:e538–e548. 2014. View Article : Google Scholar : PubMed/NCBI
21	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
22	Hu Y, Ma L, Ma G, Jiang X and Zhao C: Comparative study of human fetal and adult bone marrow derived mesenchymal stem cells. Zhonghua Xue Ye Xue Za Zhi. 23:645–648. 2002.(In Chinese). PubMed/NCBI
23	Yinjun L, Jie J and Yungui W: Triptolide inhibits transcription factor NF-kappaB and induces apoptosis of multiple myeloma cells. Leuk Res. 29:99–105. 2005. View Article : Google Scholar : PubMed/NCBI
24	Wen L, Chen Y, Zeng LL, Zhao F, Yi S, Yang LJ, Zhang BP, Zhao J, Zhao ZC and Zhang C: Triptolide induces cell apoptosis by targeting H3K4me3 and down-stream effector proteins in KM3 multiple myeloma cells. Curr Pharm Biotechnol. 17:147–160. 2015. View Article : Google Scholar : PubMed/NCBI
25	Carter BZ, Mak DH, Shi Y, Fidler JM, Chen R, Ling X, Plunkett W and Andreeff M: MRx102, a triptolide derivative, has potent antileukemic activity in vitro and in a murine model of AML. Leukemia. 26:443–450. 2012. View Article : Google Scholar : PubMed/NCBI
26	Sun L, Li H, Zhang L and Zhou H: Anticancer properties of triptolide: Inhibition of tumor-associated macrophages differentiation and cytokine production. FASEB J. 30:1193–1199. 2016.
27	Knoblich JA and Lehner CF: Synergistic action of Drosophila cyclins A and B during the G2-M transition. EMBO J. 12:65–74. 1993. View Article : Google Scholar : PubMed/NCBI
28	Hung FM, Chen YL, Huang AC, Hsiao YP, Yang JS, Chung MT, Chueh FS, Lu HF and Chung JG: Triptolide induces S phase arrest via the inhibition of cyclin E and CDC25A and triggers apoptosis via caspase- and mitochondrial-dependent signaling pathways in A375.S2 human melanoma cells. Oncol Rep. 29:1053–1060. 2013. View Article : Google Scholar : PubMed/NCBI
29	Chen Y, Vallee S, WU J, Vu D, Sondek J and Ghosh G: Inhibition of NF-kappaB activity by IkappaBbeta in association with kappaB-Ras. Mol Cell Biol. 24:3048–3056. 2004. View Article : Google Scholar : PubMed/NCBI
30	Biswas DK, Shi Q, Baily S, Strickland I, Ghosh S, Pardee AB and Iglehart JD: Activation of NF-kappa B in human breast cancer specimens and its role in cell proliferation and apoptosis. Proc Natl Acad Sci USA. 101:10137–10142. 2004. View Article : Google Scholar : PubMed/NCBI
31	Grosjean-Raillard J, Tailler M, Adès L, Perfettini JL, Fabre C, Braun T, De Botton S, Fenaux P and Kroemer G: ATM mediates constitutive NF-kappaB activation in high-risk myelodysplastic syndrome and acute myeloid leukemia. Oncogene. 28:1099–1109. 2009. View Article : Google Scholar : PubMed/NCBI
32	Yun JM, Afaq F, Khan N and Mukhtar H: Delphinidin, an anthocyanidin in pigmented fruits and vegetables, induces apoptosis and cell cycle arrest in human colon cancer HCT116 cells. Mol Carcinog. 48:260–270. 2009. View Article : Google Scholar : PubMed/NCBI
33	Dutta J, Fan Y, Gupta N, Fan G and Gélinas C: Current insights into the regulation of programmed cell death by NF-kappaB. Oncogene. 25:6800–6816. 2006. View Article : Google Scholar : PubMed/NCBI
34	Munshi NC and Avet-Loiseau H: Genomics in multiple myeloma. Clin Cancer Res. 17:1234–1242. 2011. View Article : Google Scholar : PubMed/NCBI
35	Hideshima T, Mitsiades C, Tonon G, Richardson PG and Anderson KC: Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets. Nat Rev Cancer. 7:585–598. 2007. View Article : Google Scholar : PubMed/NCBI
36	Mitsiades CS, Mitsiades NS, Munshi NC, Richardson PG and Anderson KC: The role of the bone microenvironment in the pathophysiology and therapeutic management of multiple myeloma: Interplay of growth factors, their receptors and stromal interactions. Eur J Cancer. 42:1564–1573. 2006. View Article : Google Scholar : PubMed/NCBI
37	Podar K, Chauhan D and Anderson KC: Bone marrow microenvironment and the identification of new targets for myeloma therapy. Leukemia. 23:10–24. 2009. View Article : Google Scholar : PubMed/NCBI
38	Basak GW, Srivastava AS, Malhotra R and Carrier E: Multiple myeloma bone marrow niche. Curr Pharm Biotechnol. 10:345–346. 2009. View Article : Google Scholar : PubMed/NCBI
39	Yasui H, Hideshima T, Richardson PG and Anderson KC: Novel therapeutic strategies targeting growth factor signalling cascades in multiple myeloma. Br J Haematol. 132:385–397. 2006.PubMed/NCBI
40	Podar K, Richardson PG, Hideshima T, Chauhan D and Anderson KC: The malignant clone and the bone-marrow environment. Best Pract Res Clin Haematol. 20:597–612. 2007. View Article : Google Scholar : PubMed/NCBI
41	Garcia-Gomez A, Sanchez-Guijo F, Del Cañizo MC, San Miguel JF and Garayoa M: Multiple myeloma mesenchymal stromal cells: Contribution to myeloma bone disease and therapeutics. World J Stem Cells. 6:322–343. 2014. View Article : Google Scholar : PubMed/NCBI
42	Ma JX, Sun YL, Wang YQ, Wu HY, Jin J and Yu XF: Triptolide induces apoptosis and inhibits the growth and angiogenesis of human pancreatic cancer cells by downregulating COX-2 and VEGF. Oncol Res. 20:359–368. 2013. View Article : Google Scholar : PubMed/NCBI